[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Elnemr A, Yonemura Y, Shinbo M, Nishino E: Primary retroperitoneal mullerian adenocarcinoma. Rare Tumors; 2010;2(1):e6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary retroperitoneal mullerian adenocarcinoma.
  • Mullerian tumors are extremely rare malignancies in the retroperitoneum.
  • Ultrasonography (US) and computed tomography (CT) demonstrated a 15×10 cm cystic mass in the left lower retroperitoneum.
  • Six cycles of intraperitoneal (IP) chemotherapy was administered during the last six months after diagnosis of recurrence by aspiration cytology and high serum tumor markers (CEA, CA19-9).
  • A few days ago, positron emission tomographic (PET) scanning showed evidence of local recurrence and single vertebral metastasis, so she was admitted again for systemic chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139951.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994487
  • [Keywords] NOTNLM ; adenocarcinoma / mullerian tumor / retroperitoneum
  •  go-up   go-down


2. Kumano M, Miyake H, Hara I, Furukawa J, Takenaka A, Fujisawa M: First-line high-dose chemotherapy combined with peripheral blood stem cell transplantation for patients with advanced extragonadal germ cell tumors. Int J Urol; 2007 Apr;14(4):336-8
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line high-dose chemotherapy combined with peripheral blood stem cell transplantation for patients with advanced extragonadal germ cell tumors.
  • BACKGROUND: The objective of this study was to evaluate the efficacy and safety of first-line high-dose chemotherapy (HDCT) combined with peripheral blood stem cell transplantation (PBSCT) for patients with advanced extragonadal germ cell tumors (EGGCT).
  • METHODS: Six male patients with advanced non-seminomatous EGGCT were treated with HDCT combined with PBSCT following 2-3 cycles of conventional-dose induction chemotherapy.
  • The regimens used for HDCT were carboplatin, etoposide and ifosfamide (ICE) in five patients and ICE plus paclitaxel (T-ICE) in one patient, and that for induction therapy was cisplatin, etoposide and bleomycin (PEB) in all patients.
  • Five patients underwent surgical resection of residual tumors after HDCT, yielding necrotic tissue in two, mature teratoma in two, and viable cancer tissue in one, and the surgical margin was negative in all patients.
  • Although all patients had grade 3 hematological toxicity, there was no treatment-related death by combining PBSCT.
  • CONCLUSIONS: First-line HDCT with PBSCT could be safely administered to patients with advanced EGGCT, and the antitumor effect of this treatment was comparatively favorable.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Mediastinal Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / therapy. Peripheral Blood Stem Cell Transplantation. Peritoneal Neoplasms / therapy. Retroperitoneal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Dose-Response Relationship, Drug. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17470166.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


3. Kumano M, Miyake H, Hara I, Furukawa J, Takenaka A, Fujisawa M: Stable hematopoietic recovery after peripheral blood stem cell transplantation in patients receiving high-dose chemotherapy for advanced germ cell tumors. Anticancer Res; 2006 Nov-Dec;26(6C):4965-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stable hematopoietic recovery after peripheral blood stem cell transplantation in patients receiving high-dose chemotherapy for advanced germ cell tumors.
  • AIM: The objective of this study was to evaluate the utility of CD34-positive peripheral blood stem cell transplantation (PBSCT) in the hematopoietic recovery, in patients receiving high-dose chemotherapy (HDCT), for advanced germ cell tumor (GCT).
  • PBSCs were harvested after conditioning chemotherapy followed by the administration of granulocyte colony-stimulating factor.
  • The median recovery times to white blood cells (WBC) greater than 500/microl, 1000/microl and 2000/microl were 8, 9 and 10 days, respectively, following PBSCT, while that to neutrophils greater than 500/microl and that to platelets greater than 50000/microl were 9 and 13 days, respectively, following PBSCT Only the recovery time to platelet count greater than 50000/microl was significantly affected by age; however, there were no significant differences in the recovery of WBC, neutrophils and platelets in relation to several parameters examined.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / blood. Neoplasms, Germ Cell and Embryonal / therapy. Peripheral Blood Stem Cell Transplantation. Testicular Neoplasms / blood. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Leukapheresis. Male. Mediastinal Neoplasms / blood. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / therapy. Middle Aged. Peritoneal Neoplasms / blood. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / therapy. Retroperitoneal Neoplasms / blood. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / therapy. Retrospective Studies

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214371.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


Advertisement
4. Leblanc E, Querleu D, Narducci F, Chauvet MP, Chevalier A, Lesoin A, Vennin P, Taieb S: Surgical staging of early invasive epithelial ovarian tumors. Semin Surg Oncol; 2000 Jul-Aug;19(1):36-41
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical staging of early invasive epithelial ovarian tumors.
  • This diagnosis can be obtained only after an exhaustive surgical staging procedure, performed as soon as the diagnosis of epithelial invasive ovarian carcinoma is established.
  • This staging surgery currently encompasses a peritoneal cytology, the thorough inspection of all the visceral and parietal peritoneal surfaces with biopsy of any abnormality, total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH + BSO), random peritoneal biopsies, omentectomy, appendectomy and bilateral pelvic and para-aortic lymphadenectomies, up to the left renal vein.
  • The results of this staging procedure and its indications are discussed.
  • In all of the cases, the radical removal of the pathologic adnexa is indicated, along with the complete peritoneal and retroperitoneal staging.
  • Adjuvant chemotherapy can be omitted in well-differentiated tumors with a negative staging operation, but currently it remains indicated in all other cases.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10883022.001).
  • [ISSN] 8756-0437
  • [Journal-full-title] Seminars in surgical oncology
  • [ISO-abbreviation] Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 47
  •  go-up   go-down


5. Rutigliano DN, Kayton ML, Steinherz P, Wolden S, La Quaglia MP: The use of preoperative chemotherapy in Wilms' tumor with contained retroperitoneal rupture. J Pediatr Surg; 2007 Sep;42(9):1595-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of preoperative chemotherapy in Wilms' tumor with contained retroperitoneal rupture.
  • PURPOSE: The National Wilms Tumor Study currently describes 3 indications for the use of preoperative chemotherapy: extensive caval involvement, bilateral tumors, and patients who only have a single kidney.
  • However, the management of patients who present with a contained retroperitoneal rupture is not specifically addressed.
  • This is relevant because of the strong possibility of peritoneal contamination when performing a primary resection and the resultant requirement for total abdominal radiation.
  • The use of neoadjuvant chemotherapy in this subgroup of patients may be warranted.
  • Details of their initial evaluation and therapy, resection and pathologic findings, and follow-up constitute this report.
  • All patients received preoperative chemotherapy with vincristine and dactinomycin (n = 1) plus doxorubicin (n = 2) for 4 to 6 weeks before surgical resection.
  • One patient underwent pretreatment computed tomography-guided biopsy of the kidney mass for diagnostic purposes.
  • Histopathologic analyses showed all tumors were resected with negative margins, and there was no intraoperative tumor spillage.
  • CONCLUSIONS: Neoadjuvant chemotherapy allowed for complete resection and avoidance of total abdominal radiation in 3 patients with ruptured Wilms' tumor and hematoma within the retroperitoneum.
  • These data support the use of initial chemotherapy in children with retroperitoneal rupture and hematoma of Wilms' tumor at diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / surgery. Neoadjuvant Therapy. Wilms Tumor / surgery
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Male. Retroperitoneal Space. Rupture, Spontaneous

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Surg. 2008 Feb;43(2):415-6; author reply 416-7 [18280305.001]
  • (PMID = 17848255.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Garin L, Corbinais S, Boucher E, Blanchot J, Le Guilcher P, Raoul JL: Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case. Dig Dis Sci; 2002 Dec;47(12):2760-2
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case.
  • Palliative resection was performed despite the presence of multiple retroperitoneal lymph nodes.
  • All pathology specimens exhibited an adenocarcinomatous component associated with carcinoid proliferation related to an appendicular tumor leading to the diagnosis of appendicular adenocarcinoid with ovarian, peritoneal, and nodal metastases.
  • Chemotherapy (Folfox 4 regimen) was given, and the patient improved within six weeks.
  • Presently, more than three years after the end of the treatment, the patient is still alive and in complete remission.
  • These tumors exhibit two cellular components.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendiceal Neoplasms / drug therapy. Fluorouracil / therapeutic use. Leucovorin / therapeutic use
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds. Ovarian Neoplasms / secondary

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Dec;42(6):2781-93 [728874.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):685-7 [7978019.001]
  • [Cites] Dis Colon Rectum. 1995 Aug;38(8):848-52 [7634979.001]
  • [Cites] J Surg Oncol. 1997 Sep;66(1):51-3 [9290693.001]
  • [Cites] Dis Colon Rectum. 1998 Jan;41(1):75-80 [9510314.001]
  • [Cites] Surgery. 1992 Mar;111(3):244-50 [1542852.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):663-9 [10442188.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • (PMID = 12498298.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


7. Engin G, Asoglu O, Kapran Y, Mert G: A gastrointestinal stromal tumor with mesenteric and retroperitoneal invasion. World J Surg Oncol; 2007;5:121
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A gastrointestinal stromal tumor with mesenteric and retroperitoneal invasion.
  • BACKGROUND: Gastrointestinal stromal tumors are rare visceral sarcomas arising in the gastrointestinal tract wall.
  • In this report we present a case of gastrointestinal stromal tumors with mesenteric and retroperitoneal invasion, describe and discuss its computed tomography findings.
  • Abdominal computed tomography showed multiple, well-defined, soft tissue masses with homogenous and heterogeneous pattern, in the mesenteric and retroperitoneal areas.
  • Unlike specific features of gastrointestinal stromal tumor, renal obstruction and atypical central calcification without chemotherapy that has not been yet described were seen in this case.
  • Computed tomography did not reveal liver metastases and/or the lymph nodes with pathological size.
  • CONCLUSION: When intraabdominal, multiple, large (>5 cm), well-circumscribed, homogenous or heterogeneous mass lesions without ascites, omental caking and lymph nodes metastases were seen, gastrointestinal stromal tumors should be considered in the differential diagnosis.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Neoplasm Invasiveness / pathology. Peritoneal Neoplasms / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Abdominal Pain / diagnosis. Abdominal Pain / etiology. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Laparotomy. Male. Mesentery. Middle Aged. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Control. 2005 Apr;12(2):111-5 [15855894.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):566-78 [15781488.001]
  • [Cites] Pol J Pathol. 2005;56(2):51-61 [16092666.001]
  • [Cites] Eur J Surg Oncol. 2006 Apr;32(3):310-4 [16414236.001]
  • [Cites] Radiographics. 2006 Mar-Apr;26(2):481-95 [16549611.001]
  • [Cites] World J Gastroenterol. 2007 Apr 14;13(14):2077-82 [17465451.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):211-22 [10680889.001]
  • [Cites] Mod Pathol. 2000 May;13(5):577-85 [10824931.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1134-42 [11048809.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • [Cites] Gastrointest Endosc. 2002 Jan;55(1):37-43 [11756912.001]
  • [Cites] Radiology. 2003 Feb;226(2):527-32 [12563150.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):703-8 [12760289.001]
  • [Cites] Eur Radiol. 2003 Jul;13(7):1669-78 [12835984.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1178-86 [14515284.001]
  • [Cites] World J Gastroenterol. 2004 Aug 15;10(16):2417-8 [15285033.001]
  • [Cites] Eur Radiol. 2004 Oct;14(10):1926-9 [15300393.001]
  • [Cites] Hum Pathol. 1992 Jul;23(7):762-7 [1612575.001]
  • [Cites] Am J Surg Pathol. 1993 Jun;17(6):588-94 [8333557.001]
  • [Cites] Mod Pathol. 1997 Mar;10(3):200-9 [9071727.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):407-16 [9130987.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):82-7 [9888707.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):937-45 [10435564.001]
  • [Cites] AJR Am J Roentgenol. 2005 Mar;184(3):803-11 [15728601.001]
  • [Cites] Eur Radiol. 2005 Jul;15(7):1407-14 [15761716.001]
  • (PMID = 17958889.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2164961
  •  go-up   go-down


8. Aguilera D, Hayes-Jordan A, Anderson P, Woo S, Pearson M, Green H: Outpatient and home chemotherapy with novel local control strategies in desmoplastic small round cell tumor. Sarcoma; 2008;2008:261589

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient and home chemotherapy with novel local control strategies in desmoplastic small round cell tumor.
  • This report illustrates novel chemotherapy and local control interventions in a 5-year old patient.
  • The patient presented with massive ascites and >1000 abdominal tumors.
  • Neoadjuvant chemotherapy included vincristine (1.5 mg/m(2)), ifosfamide (3 g/m(2)/day x 3), dexrazoxane/doxorubicin (750/75 mg/m(2)), and etoposide (150 mg/m(2)).
  • Continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin (100 mg/m(2)) was given after extensive cytoreductive surgery.
  • This was followed by irinotecan (10 mg/m(2)/day x 5 x 2 weeks) + temozolomide monthly x 2, then abdominal radiation 30 Gy with simultaneous temozolomide (100 mg/m(2)/day x 5).
  • Except for initial chemotherapy, subsequent courses were in the outpatient setting.
  • Focal retroperitoneal relapse at 18 months was treated with IMRT with bevacizumab (5 mg/kg) and 2 perihepatic metastases with radio frequency ablation/cryoablation followed by chronic outpatient maintenance chemotherapy (valproic acid, cyclophosphamide, and rapamycin).
  • This is a novel approach to the treatment of children with massive abdomino-pelvic DSRCT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 2003 Nov;41(5):476-7 [14515395.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):605-21, xi [14567020.001]
  • [Cites] Int J Oncol. 2004 Mar;24(3):609-13 [14767545.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):840-8 [14871959.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] Oncology. 2004;67(3-4):231-42 [15557784.001]
  • [Cites] J Pediatr Surg. 2005 Jan;40(1):251-5 [15868593.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):703-7 [16369989.001]
  • [Cites] J Oncol Pharm Pract. 2005 Sep;11(3):111-9 [16390599.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S68-73 [16399436.001]
  • [Cites] Pediatr Blood Cancer. 2007 Sep;49(3):274-9 [16685737.001]
  • [Cites] Nat Rev Drug Discov. 2006 Oct;5(10):835-44 [17016424.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5 Suppl 10):S35-40 [17145523.001]
  • [Cites] Curr Oncol Rep. 2006 Jul;8(4):310-5 [17254532.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):254-8 [17262795.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):112-9 [8129481.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2837-40 [8187063.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):799-806 [12610177.001]
  • [Cites] Scand J Surg. 2003;92(2):178-9 [12841562.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):2963-9 [8221562.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1526-31 [8622067.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3028-36 [9738572.001]
  • [Cites] Ann Clin Lab Sci. 1998 Nov-Dec;28(6):386-93 [9846206.001]
  • [Cites] Med Pediatr Oncol. 1999 Nov;33(5):500-3 [10531577.001]
  • (PMID = 18566684.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2430011
  •  go-up   go-down


9. Aurello P, Cicchini C, De Angelis R, D'Angelo F, Ramacciatos G, Valabrega S, Indinnimeo M: Synchronous and metachronous retroperitoneal sarcomas: two case reports. Anticancer Res; 2002 Jul-Aug;22(4):2409-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous and metachronous retroperitoneal sarcomas: two case reports.
  • BACKGROUND: Retroperitoneal sarcomas represent less than 1% of all diagnosed human neoplasias.
  • They are generally malignant and can infiltrate retroperitoneal structures.
  • The value of chemotherapy and radiotherapy are difficult to evaluate and the dominating factor in the outcome is the ability to resect the tumor.
  • Recurrence of sarcoma at the operative site and on peritoneal surfaces is a prominent cause of morbidity and mortality.
  • CASE REPORTS: Here we report two patients who underwent surgery for retroperitoneal sarcoma.
  • In each of them at least two primary retroperitoneal tumors were diagnosed.
  • The neoplasms were histologically different, thus they cannot be considered local recurrence but rather primary tumors.
  • In explanation of the occurrence of satellite tumors and multiple primary tumors, a virus-associated etiology or polyclonality of the tumor or pluripotentiality of tumor stem cells should be considered.
  • [MeSH-major] Neoplasms, Second Primary / surgery. Retroperitoneal Neoplasms / surgery. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174935.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


10. Yokoi M, Hosokawa K, Funaki H, Yoshitani S, Kinami S, Omote K, Ueda N, Nakano Y, Kosaka T, Minato H: [A case of retroperitoneal dedifferentiated liposarcoma successfully treated with IFM and CDDP]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2114-6
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of retroperitoneal dedifferentiated liposarcoma successfully treated with IFM and CDDP].
  • Physical examination revealed an abdominal distention and ascites, and CT showed multiple large retroperitoneal masses.
  • The patient was diagnosed with retroperitoneal liposarcoma.
  • Multiple tumors in the peritoneum were noted.
  • Large dark red tumors that were hemorrhagic were resected, but the yellowish tumors were unresectable.
  • One month postoperatively, peritoneal dissemination increased including nodular infiltration of the artificial anus and multiple hepatic metastases.
  • Despite VAC chemotherapy (VCR 1.5 mg, ACD 0.5 mg, CPA 900 mg), progressive disease (PD) was noted.
  • As second-line chemotherapy, weekly IFM (2 g)+CDDP (30 mg) was given.
  • A partial response (PR) against peritoneal dissemination was achieved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liposarcoma / drug therapy. Retroperitoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037341.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


11. Baratti D, Pennacchioli E, Kusamura S, Fiore M, Balestra MR, Colombo C, Mingrone E, Gronchi A, Deraco M: Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol; 2010 Dec;17(12):3220-8
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
  • BACKGROUND: Unlike novel molecular-targeted therapies for metastatic gastrointestinal stromal tumors (GIST), conventional treatments for peritoneal sarcomatosis (PS) are mostly ineffective.
  • As with carcinomatosis of epithelial origin, a rationale base supports an aggressive locoregional treatment of PS, but the use of CRS and HIPEC in this setting is still controversial.
  • We assessed the outcome of clinically and pathologically homogeneous subsets of patients with PS uniformly treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • PS originated from GIST (pre-imatinib era) in 8 patients, uterine leiomyosarcoma (ULS) in 11, retroperitoneal liposarcoma (RPLP) in 13, and other sarcoma in 5.
  • After median follow-up of 104 (range, 1-131) months, peritoneal disease progression occurred in 16 patients, distant metastases in 5, and both in 13.
  • RPLP had the best overall survival (median, 34 months) but 100% peritoneal relapse; GIST had dismal overall, local-regional-free and distant-free survival; ULS had the higher proportion of long survivors and best local-regional-free survival.
  • CONCLUSIONS: Overall, results of CRS and HIPEC did not compare favorably to those of conventional therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Leiomyosarcoma / therapy. Peritoneal Neoplasms / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Liposarcoma / classification. Liposarcoma / pathology. Liposarcoma / therapy. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Prospective Studies. Retroperitoneal Neoplasms / classification. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / therapy. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Surg Oncol. 2011 Dec;18 Suppl 3:S327. Alessanrdro, Gronchi [corrected to Gronchi, Alessandro]
  • (PMID = 20585874.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; Retroperitoneal liposarcoma
  •  go-up   go-down


12. Mandić A, Djurdjević S, Popov M, Krnojelać D, Kukić B: Retroperitoneal malignant schwannoma and peritoneal malignant mesothelioma: a case report. J BUON; 2004 Jan-Mar;9(1):91-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal malignant schwannoma and peritoneal malignant mesothelioma: a case report.
  • Malignant schwannoma and peritoneal malignant mesothelioma (MM) are very rare tumors.
  • Malignant peripheral nerve sheath tumors (MPNSTs) commonly are large in size.
  • MM arises primarily from the surface serosal cells of the pleural, peritoneal, and pericardial cavities.
  • The patient was operated on for second time and MM was diagnosed as second primary tumor, along with recurrence of the malignant schwannoma.
  • The patient received postoperative adjuvant external beam radiotherapy and chemotherapy.
  • Despite combined-modality treatment the disease progressed and the patient was operated on for third time 2.5 years after the first operation with partial tumor resection.
  • Early diagnosis of these two types of tumors is very difficult because of unspecific clinical symptoms.
  • Singlemodality therapy of these tumors has shown poor results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17385835.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


13. Billmire D, Vinocur C, Rescorla F, Cushing B, London W, Schlatter M, Davis M, Giller R, Lauer S, Olson T, Children's Oncology Group (COG): Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg; 2004 Mar;39(3):424-9; discussion 424-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study.
  • PURPOSE: The aim of this study was to perform an evaluation of outcome and the role of surgical staging components in malignant germ cell tumors (GCT) of the ovary in children and adolescents.
  • Stage I-II patients were treated with surgical resection and 4 cycles of standard dose cisplatin (100 mg/m2/cycle), etoposide, and bleomycin (PEB) chemotherapy.
  • Stage III-IV patients were treated with surgical resection and randomly assigned to chemotherapy with PEB or high-dose cisplatin (200 mg/m2/cycle) with etoposide and bleomycin (HDPEB).
  • Patients unresectable at diagnosis had second-look operation after 4 cycles of chemotherapy if residual tumor was seen on imaging studies.
  • RESULTS: There were 131 patients with ovarian primary tumors of 515 entered on these studies.
  • Surgical omissions resulting in protocol noncompliance resulted from failure to biopsy bilateral nodes (97%), no omentectomy (36%), no peritoneal cytology (21%), no contralateral ovary biopsy (59%).
  • More aggressive procedure than recommended by guidelines included total hysterectomy and bilateral salpingo-oophorectomy in 6 patients and retroperitoneal node dissection in 10 patients.
  • CONCLUSIONS: Pediatric ovarian malignant GCT (stages I-IV) have excellent survival with conservative surgical resection and platinum-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Germinoma / pathology. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Female. Humans. Infant. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15017564.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


14. Sasaki K, Doi T, Matsumoto G, Tsuruta K, Okamoto A, Funada N: [Metastatic gastrointestinal stromal tumors responded to the treatment with STI571 after polysurgery for recurrent lesions--report of two cases]. Gan To Kagaku Ryoho; 2003 Jul;30(7):1021-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic gastrointestinal stromal tumors responded to the treatment with STI571 after polysurgery for recurrent lesions--report of two cases].
  • Two cases of metastatic gastrointestinal stromal tumors (GIST) that had responded to the treatment with STI571 were presented.
  • For 21 months after surgery, the patient received repeated tumor removal four times due to hepatic metastasis and/or peritoneal recurrence.
  • Thereafter, the treatment with STI571 at a dose of 400 mg/day was initiated.
  • Eight months after the administration, only a small hepatic metastasis was detected on a film of CT scan, and any signs of peritoneal recurrence were observed.
  • Case 2 was a 61-year-old man who underwent emergency surgery for a retroperitoneal tumor that had caused massive intestinal hemorrhage resulting in critical shock.
  • The patient underwent the surgery three times for recurrent lesions.
  • Six months after treatment the hepatic lesions were shrunk, but the number of retroperitoneal lesions increased.
  • These clinical observations suggest that ST1571 therapy for metastatic lesions from GIST may be preferred over aggressive, repeated tumor removal.
  • [MeSH-major] Liver Neoplasms / drug therapy. Pyrimidines / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Benzamides. Combined Modality Therapy. Drug Administration Schedule. Female. Gastrectomy. Hepatectomy. Humans. Imatinib Mesylate. Male. Middle Aged. Piperazines. Proto-Oncogene Proteins c-kit / analysis. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12894723.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


15. Cagol PP, Pasqual E, Bacchetti S: Natural history of the neoplastic locoregional disease: clinical and pathological patterns. J Exp Clin Cancer Res; 2003 Dec;22(4 Suppl):1-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A great number of locoregional treatments are currently carried out to treat a variety of locoregional neoplastic diseases.
  • Indications are the treatment of primary and metastatic liver tumors, peritoneal mesotheliomas, peritoneal spread of ovarian carcinomas, peritoneal recurrences of gastrointestinal cancers, peritoneal spread of retroperitoneal sarcomas, melanomas and sarcomas of the limbs, some primary tumors of the brain, breast, kidney, lung, bladder.
  • But to deal with locoregional therapy demands to clarify some features of these malignancies.
  • At this regard, the knowing of their natural history can be crucial to guide the choice of the correct locoregional treatment.
  • For instance peritoneal carcinomatosis is considered as a main step of disease progression for ovarian cancer and often for gastrointestinal tumors as well.
  • However when the tumors are confined on the surface of the peritoneum, basing on their own natural history, they can be considered as localized diseases.
  • Selected patients with peritoneal neoplastic seeding, previously considered in a preterminal condition, can be considered as candidates for curative treatment, using cytoreductive surgical tecniques (16) and hyperthermic intraperitoneal chemotherapy (19).
  • The same can be thought about others primary or metastatatic tumors when the neoplastic deposits are confined within a definite site or region of the body.
  • In this paper the main aspects of liver metastases and peritoneal carcinomatosis natural history, two of the most frequently recognized indications for locoregional therapy, are presented.
  • [MeSH-major] Liver Neoplasms / secondary. Neoplasm Metastasis / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / therapy. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16767897.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 20
  •  go-up   go-down


16. Knudsen AL, Bülow S: [Desmoid tumor in familial adenomatous polyposis]. Ugeskr Laeger; 2000 Oct 16;162(42):5628-31
Genetic Alliance. consumer health - Familial Polyposis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Desmoid tumors (DT) are rare benign tumors that do not metastasize, but tend to invade locally.
  • DT are frequently seen in patients with familial adenomatous polyposis (FAP), and diagnosis and treatment are often difficult.
  • METHOD: The article presents the clinical picture, diagnosis and treatment of DT in patients registered in the Danish Polyposis Register by the end of 1999.
  • RESULTS: Twenty-seven of 486 patients (6%) had DT.
  • Eighteen patients were alive at the time of evaluation.
  • DT were found in the mesentery in 42%, in the abdominal wall in 40%, in the retroperitoneum in 8% and only 10% on the extremities.
  • Fifty percent of the patients had complications (intestinal obstruction, hydronephrosis or fistulas), and 2/9 deaths were caused by DT.
  • Ninety-three percent were treated with surgery, NSAIDs, antioestogenic drugs, chemotherapy or radiotherapy, but all modalities proved disappointing, except for treatment with a combination of the NSAID sulindac and tamoxifen.
  • DISCUSSION: Surgical excision is recommended in patients with DT in the abdominal wall.
  • First line treatment of mesenteric DT is Clinoril in combination with tamoxifen.
  • Elective surgery may be considered in patients with a small well-defined DT with no signs of invasion of vital structures, and in patients with imminent bowel ischaemia or obstruction.
  • The prognosis for mesenteric DT is grave, and improvement of the therapeutic strategy awaits current international studies.
  • [MeSH-major] Abdominal Neoplasms. Adenomatous Polyposis Coli. Fibromatosis, Aggressive. Peritoneal Neoplasms. Retroperitoneal Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Colectomy. Colonic Neoplasms / complications. Colonic Neoplasms / diagnosis. Colonic Neoplasms / surgery. Combined Modality Therapy. Female. Humans. Male. Prognosis. Registries

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11059301.001).
  • [ISSN] 0041-5782
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] DENMARK
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Steed H, Oza A, Chapman WB, Yaron M, De Petrillo D: Female adnexal tumor of probable wolffian origin: a clinicopathological case report and a possible new treatment. Int J Gynecol Cancer; 2004 May-Jun;14(3):546-50
Genetic Alliance. consumer health - Wolffian tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Female adnexal tumor of probable wolffian origin: a clinicopathological case report and a possible new treatment.
  • Female adnexal tumors of probable wolffian origin (FATWOs) are rare tumors arising in the broad ligament from the remnants of the mesonephric duct.
  • The tumor recurred within 2 years and was treated with multiple chemotherapy regimens, including a platinum-based drug, and surgery for progressive disease.
  • Gleevac therapy, a tyrosine kinase inhibitor, was prescribed, and she developed severe persistent lower abdominal pain 2 months later.
  • She underwent a hysterectomy and debulking of retroperitoneal masses.
  • She is currently asymptomatic, without evidence of disease 10 months after surgery, continuing on Gleevac therapy.
  • FATWOs are very rare tumors.
  • There is limited knowledge about the optimal treatment for this neoplasm.
  • Our patient's favorable response to Gleevac therapy supports the concept of targeted molecular therapy in patients with c-kit-positive FATWO tumors.
  • [MeSH-major] Neoplasm Recurrence, Local / diagnosis. Peritoneal Neoplasms / diagnosis. Wolffian Ducts
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Combined Modality Therapy. Diagnosis, Differential. Enzyme Inhibitors / therapeutic use. Female. Humans. Protein-Tyrosine Kinases / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15228432.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


18. Menczer J, Chetrit A, Sadetzki S, National Israel Ovarian Cancer Group: Ovarian carcinoma apparently confined to the ovaries--the accuracy of surgical staging in Israel. Eur J Gynaecol Oncol; 2009;30(4):375-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In order to allot an ovarian malignancy to FIGO Stage I, in addition to abdominal exploration and the basic operation, it is also necessary to do peritoneal washings for cytological examination, random peritoneal biopsies (including diaphragmatic assessment) and omental and retroperitoneal lymph node assessment.
  • The most commonly performed staging procedure was omental assessment (85.2%) while peritoneal biopsy was the least common one (34.1%).
  • CONCLUSION: Although the data are from a decade ago, they seem to indicate the need for an increased awareness of the necessity for accurate surgical staging of tumors apparently confined to the ovaries since it can identify a group of patients who require surgical therapy alone and who can be spared the complications, inconvenience and cost of adjuvant chemotherapy.
  • [MeSH-major] Carcinoma / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19761125.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Investigator] Anderman S; Alteras M; Anteby S; Atad J; Avni A; Bar-Am A; Beck D; Beller U; Ben-Baruch G; Ben-David Y; Ben-Shlomo I; Biran H; Ben Ami M; Chetrit A; Cohen S; Cohen S; Dgani R; Fishler Y; Fishman A; Friedman E; Gemer O; Gershoni R; Halperin R; Hirsh-Yechezkel G; Idelman D; Katan R; Kopilovic Y; Lahad E; Geva LL; Levavi H; Levy T; Levit A; Lifschitz-Mercer B; Lubin F; Leviatan Z; Marcovich J; Menczer J; Modan B; Nitzan H; Oetinger M; Perez T; Piura B; Schneider D; Shteiner M; Tal Z; Yaffe C; Yanai I; Zohar S
  •  go-up   go-down


19. Rossi CR, Casali P, Kusamura S, Baratti D, Deraco M: The consensus statement on the locoregional treatment of abdominal sarcomatosis. J Surg Oncol; 2008 Sep 15;98(4):291-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The consensus statement on the locoregional treatment of abdominal sarcomatosis.
  • Abdominal sarcomatosis (AS) is a rare condition characterized by soft tissue sarcoma spreading throughout the abdomen, in the absence of extra-abdominal dissemination.
  • Retroperitoneal sarcomas, pelvic sarcomas, particularly uterine leiomyosarcoma, and gastrointestinal stromal tumors (GISTs) most frequently give rise to AS.
  • Systemic chemotherapy is the standard of care for AS from non-GIST sarcomas, but with an essentially palliative aim and major limitations.
  • Innovative targeted therapies has deeply affected the natural history of GIST, at least in prolonging significantly survival in responsive patients.
  • In this context, the notion that abdominal spread in the lack of extra-peritoneal lesions may typically occur in a number of patients, along with the dismal prognosis generally carried by AS, has prompted a few centers to perform cytoreductive surgery and perioperative intraperitoneal chemotherapy.
  • To date, the rarity of these presentations makes it difficult to evaluate the clinical results and the role of combined local-regional treatment is still a matter of debate.
  • A questionnaire was placed on the website of the 5th International Workshop on Peritoneal Surface Malignancy and the experts voted via internet.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / surgery. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced. Sarcoma / drug therapy. Sarcoma / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Consensus. Humans. Infusions, Parenteral. Practice Guidelines as Topic

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726899.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


20. Heidenreich A, Krege S, Flasshove M: [Interdisciplinary cooperation in the treatment of complex patients with advanced testicular germ cell tumor]. Urologe A; 2004 Dec;43(12):1521-30
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interdisciplinary cooperation in the treatment of complex patients with advanced testicular germ cell tumor].
  • [Transliterated title] Interdisziplinäre Kooperation in der Therapie von komplexen Patienten mit fortgeschrittenem testikulärem Keimzelltumor.
  • Testicular germ cell tumors represent the classic example of a curable solid cancer even in the metastatic stage.
  • Standardization of diagnosis and therapy should be further optimized due to the recently published interdisciplinary national and European guidelines.
  • Besides realization of standardized guidelines, treatment of patients with extensive primary disease or recurrent germ cell tumors following standard therapy requires comprehensive knowledge in conservative and surgical management, which is basically only available at specialized cancer centers.
  • When treating these patients, one has to consider that inadequately administered chemotherapy (dosage, length of cycles, number of cycles) cannot be compensated for by surgery and that inadequately performed retroperitoneal lymphadenectomy or residual tumor resection cannot be compensated for by chemotherapy.
  • In any case, suboptimal primary therapy will result in inferior cure rates and an unnecessarily increased mortality rate.
  • [MeSH-major] Lymph Node Excision / methods. Neoplasms, Germ Cell and Embryonal / secondary. Neoplasms, Germ Cell and Embryonal / therapy. Patient Care Team / organization & administration. Practice Patterns, Physicians' / organization & administration. Testicular Neoplasms / drug therapy. Testicular Neoplasms / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy / methods. Cooperative Behavior. European Union. Germany. Humans. Lymphatic Metastasis. Male. Middle Aged. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Peritoneum / surgery. Practice Guidelines as Topic. Severity of Illness Index. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1990 Nov;8(11):1777-81 [1700077.001]
  • [Cites] Urologe A. 1998 Nov;37(6):625-8 [9887491.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2647-57 [11352956.001]
  • [Cites] Br J Urol. 1980 Feb;52(1):38-44 [7426950.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1392-9 [10424741.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Aug;127(8):475-81 [11501746.001]
  • [Cites] Eur Urol. 2005 Jan;47(1):64-71 [15582251.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2500-4 [9667270.001]
  • [Cites] J Urol. 2004 May;171(5):1835-8 [15076288.001]
  • [Cites] Aktuelle Urol. 2004 Apr;35(2):141-50; quiz 151-2 [15146380.001]
  • [Cites] Eur Urol. 2001 Oct;40(4):372-91 [11713391.001]
  • [Cites] Ann Oncol. 1997 Jan;8(1):41-7 [9093706.001]
  • [Cites] Eur Urol. 2000 May;37(5):582-94 [10765098.001]
  • [Cites] Lancet. 1990 Oct 20;336(8721):1011 [1976994.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):599-605 [12056711.001]
  • [Cites] Cancer. 1991 Jan 1;67(1 Suppl):303-9 [1984832.001]
  • [Cites] J Urol. 2004 May;171(5):1839-41 [15076289.001]
  • [Cites] Eur Urol. 2003 Aug;44(2):233-44 [12875944.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):531-8 [9261521.001]
  • [Cites] Cancer. 1991 Jan 1;67(1 Suppl):220-4 [1984823.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):520-30 [12209744.001]
  • [Cites] J Urol. 1987 Jul;138(1):77-82 [3599225.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3450-6 [10550141.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2546-52 [9215823.001]
  • [Cites] J Urol. 1982 Aug;128(2):315-20 [7109099.001]
  • [Cites] J Natl Cancer Inst. 1999 May 19;91(10):839-46 [10340903.001]
  • [Cites] Br J Cancer. 1995 Nov;72(5):1307-11 [7577488.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1287-93 [9552027.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):852-5 [10597210.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1377-99 [15319245.001]
  • [Cites] Eur J Cancer. 2000 Jul;36(11):1389-94 [10899652.001]
  • [Cites] N Engl J Med. 1987 Dec 3;317(23):1433-8 [2446132.001]
  • (PMID = 15592709.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 35
  •  go-up   go-down


21. Déjardin Ddel C, Carbajo-Ferré EM, González MH, Pereferrer FS, Blasco SB, Pérez JS, Marín AS, Calvet JD, Lara CD, Lanao MA, Moreno VV: Massive intraperitoneal stromal tumour: two-year follow-up. Surgeon; 2007 Jun;5(3):182-5
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Until recently, they were only treated surgically but, nowadays, for high grade tumours, we can consider wide excision, not only as a palliative measure, but also to enable subsequent treatment with Imatinib mesylate.
  • METHODS: We describe the case of a patient with a high-grade GIST, who, two years after undergoing surgery and medical treatment, is still in remission.
  • Computerised axial tomography (CT) of the abdomen detected the presence of multiple heterogeneous solid masses of various sizes but no localised retroperitoneal adenopathies.
  • The patient had visceral, parietal and peritoneal dissemination.
  • Two years after cytoreduction surgery, the patient is well and free of obvious disease and has shown a good tolerance to pharmacological treatment.
  • CONCLUSIONS: Imatinib mesylate has revolutionised the treatment of GIST and offers good palliation and prolongation of overall survival.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Biomarkers, Tumor / blood. Female. Humans. Imatinib Mesylate. Middle Aged. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575672.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


22. Djordjevic B, Euscher ED, Malpica A: Growing teratoma syndrome of the ovary: review of literature and first report of a carcinoid tumor arising in a growing teratoma of the ovary. Am J Surg Pathol; 2007 Dec;31(12):1913-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the first case of a secondary tumor arising from a peritoneal nodule of mature teratoma in a patient with growing teratoma syndrome (GTS) of the ovary.
  • The patient originally presented 19 years ago with an immature teratoma of the ovary and positive retroperitoneal lymph nodes.
  • After surgery and chemotherapy, mature teratomas recurred as abdominal and pelvic masses after 1, 6, and 19 years.
  • Upon the last recurrence, a trabecular carcinoid tumor developed in a mature teratoma associated with the liver.
  • This case illustrates the importance of long-term follow-up for patients with GTS of the ovary, where the recurrent masses can appear many years after the primary tumor, compress the abdominal and pelvic structures and give rise to secondary neoplasms.
  • On the basis of our review of ovarian GTS cases in the literature, we have found that ovarian GTS nodules tend to appear for the first time within 2 years of the initial primary.
  • This new information may help identify and screen women with germ cell tumors of the ovary at risk for GTS.
  • [MeSH-major] Carcinoid Tumor / pathology. Liver Neoplasms / secondary. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Teratoma / secondary
  • [MeSH-minor] Abdominal Neoplasms / secondary. Adult. Age of Onset. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Pelvic Neoplasms / secondary


23. Szkandera J, Ploner F, Bauernhofer T, Kasparek AK, Payer F, Balic M, Knechtel G, Gerger A, Gallè G, Samonigg H, Hofmann G: Paraneoplastic limbic encephalitis in a patient with extragonadal choriocarcinoma--significance of onconeural antibodies. Onkologie; 2010;33(8-9):452-4
Genetic Alliance. consumer health - Limbic encephalitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Paraneoplastic limbic or brainstem encephalitis is considered to be an autoimmune-mediated disorder of the nervous system associated with different types of cancer including germ cell tumors.
  • Further examinations including ultrasound of the abdomen led to the detection of a retroperitoneal mass.
  • The patient underwent curative chemotherapy, but although the cancer therapy was successful, the neurologic disorders did not improve.
  • The detection of these antibodies supports the diagnosis of a paraneoplastic syndrome, and may lead to the earlier identification of an otherwise hidden extragonadal germ cell tumor.
  • [MeSH-major] Antibodies, Neoplasm / immunology. Antigens, Neoplasm / immunology. Limbic Encephalitis / diagnosis. Limbic Encephalitis / immunology. Nerve Tissue Proteins / immunology. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / immunology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Neoplasms, Gonadal Tissue

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20838061.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Ma2 antigen; 0 / Nerve Tissue Proteins
  •  go-up   go-down


24. Brisse HJ, Schleiermacher G, Sarnacki S, Helfre S, Philippe-Chomette P, Boccon-Gibod L, Peuchmaur M, Mosseri V, Aigrain Y, Neuenschwander S: Preoperative Wilms tumor rupture: a retrospective study of 57 patients. Cancer; 2008 Jul 1;113(1):202-13
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The authors performed a retrospective analysis of 57 children with clinical and/or radiologic (computed tomography [CT]) signs of preoperative tumor rupture of a series of 250 patients enrolled in Wilms SIOP protocols at their institution.
  • The site of rupture on imaging was retroperitoneal only in 48 patients and both retroperitoneal and intraperitoneal in 7 patients.
  • Surgery was performed after chemotherapy in 55 of 57 patients.
  • Peritoneal disease recurrence occurred in 3 of 57 patients, including 2 patients with stage III tumors who had initial intraperitoneal rupture and 1 patient with a stage I tumor.
  • Among the 48 patients who had radiologic signs of retroperitoneal-only rupture, the final pathologic stage was stage III in 22 patients, stage II in 9 patients, and stage I in 17 patients, and no abdominal disease recurrence was observed, although only 23 of 48 patients received flank radiotherapy.
  • The 5-year local control rate was significantly higher in patients who had retroperitoneal-only rupture compared with patients who had intraperitoneal rupture (100% vs 83.3%; standard error, +/-15.2%; P = .0015).
  • Intraperitoneal rupture was diagnosed accurately with CT and was associated with a significant risk of peritoneal disease recurrence.
  • In contrast, patients who have radiologic signs of localized retroperitoneal-only rupture at diagnosis most likely should not be upstaged, and their treatment may be determined according to pathologic stage only.
  • [MeSH-major] Kidney Neoplasms / complications. Rupture, Spontaneous / complications. Wilms Tumor / complications
  • [MeSH-minor] Chemotherapy, Adjuvant. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Infant. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Preoperative Care. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Copyright) 2008 American Cancer Society.
  • (PMID = 18457331.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Kikuchi Y: The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study. Int J Gynecol Cancer; 2009 Nov;19(8):1353-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pure-type clear cell carcinoma (CCC) has been recognized as a distinct subtype of ovarian cancer, showing resistance to conventional platinum-based chemotherapy and resulting in poor prognosis.
  • Among pT1 M0 tumors, retroperitoneal lymph node status was negative in 125 cases (pN0, 63%), positive in 10 cases (pN1, 5%), and unknown in 64 cases (pNx, 32%).
  • Multivariate analysis revealed that peritoneal cytology status was the only independent prognostic factor for progression-free survival (P = 0.04), but completion of surgical staging procedures was not a prognostic factor.
  • Our study implied that complete surgical staging enabled us to distinguish a high-risk group of recurrence in pT1 M0 CCC; however, the procedure could not improve OS.
  • Although the study was a limited retrospective study, the impact of peritoneal cytology status was more important than complete surgical staging procedure in CCC patients.
  • More effective treatment modality was warranted, especially for CCC cases positive for malignant peritoneal cytology.
  • [MeSH-major] Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / surgery. Ovarian Neoplasms / mortality. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Antineoplastic Agents / therapeutic use. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / secondary. Cystadenocarcinoma, Serous / surgery. Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009889.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


26. Lygidakis NJ, Bhagat AD, Vrachnos P, Grigorakos L: Multiorgan resection for advanced abdominal malignancies--is it feasible? Hepatogastroenterology; 2007 Jul-Aug;54(77):1353-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: In everyday clinical practice many unfortunate patients present with advanced abdominal malignancies and are referred to a medical oncologist for palliative chemoradiotherapy and very few of them are offered surgical treatment.
  • The aim of this study was to assess the feasibility and effect of aggressive surgical management with adjuvant chemotherapy in advanced abdominal malignancies requiring resection of one or more organs along with the primary organ of the disease.
  • The patients with ovarian and uterine (n=18) malignancy underwent resection of colon (5), omentum (18), distal pancreatectomy and splenectomy (2), cystectomy (4), parietal peritoneal excision (9), small bowel excision in various combinations along with radical hysterectomy.
  • Twelve patients with advanced colorectal carcinoma (n=12) along with abdominoperineal excision, anterior resection or colonic resection underwent cystectomy (3), hysterectomy (4), small bowel resection (4), hepatic resection (7) or parietal peritoneal excision (4) in various combinations.
  • A total of 14 patients with gastric and gastroesophageal junction malignancy (n=14) underwent gastrectomy or gastroesophagectomy with omentectomy (14), distal pancreatico-splenectomy (5), hepatic resection (9), transverse colectomy (2) and parietal peritoneal excision (2) due to advanced disease.
  • Patients with pancreatic carcinoma (n=12) underwent Whipple's pancreaticoduodenectomy or distal pancreatectomy with hepatic resection (6), transverse colectomy (1), splenectomy (3), left nephrectomy and adrenalectomy (3), small bowel excision (1) and parietal peritoneal excision (3).
  • Along with excision of nonsolid organ retroperitoneal tumors (n=6) the organs resected were left kidney with adrenal (2), spleen (2) right kidney and adrenal (2), segmental inferior vena cava (1) and colon (2).
  • All patients (except those who died in the early postoperative period) received adjuvant chemotherapy (43) or chemobiologic therapy (12) or radiotherapy.
  • CONCLUSIONS: Aggressive surgical intervention by multiorgan resection and adjuvant chemo or chemobiological therapy is a feasible option in patients with advanced abdominal malignancies with statistically improved survival rate.
  • Furthermore, it helps in getting better response to therapeutic manipulations and improved quality of life of the patients.
  • [MeSH-major] Abdominal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708253.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


27. Kurzer E, Leveillee RJ, Bird VG: Combining hand assisted laparoscopic nephroureterectomy with cystoscopic circumferential excision of the distal ureter without primary closure of the bladder cuff--is it safe? J Urol; 2006 Jan;175(1):63-7; discussion 67-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combining hand assisted laparoscopic nephroureterectomy with cystoscopic circumferential excision of the distal ureter without primary closure of the bladder cuff--is it safe?
  • PURPOSE: We have previously described our technique of combining HAL-NU using early ureteral ligation with simultaneous cystoscopic circumferential excision of the distal intramural ureter without primary closure of the bladder cuff.
  • The locations of recurrence and need for adjuvant treatment were assessed.
  • Of the patients 20 (49%) had bladder tumors postoperatively.
  • Two patients were found to have advanced stage disease, leading to chemotherapy with radiation therapy in 1 and radical cystectomy in the other at 4 and 14 months, respectively.
  • One patient was found to have distant metastases to the liver and retroperitoneal lymph nodes 2 years after surgery.
  • No patients were found to have local pelvic or peritoneal metastases.
  • CONCLUSIONS: HAL-NU with cystoscopic excision of the distal ureter is feasible, safe and effective for upper tract transitional cell carcinoma.
  • There is no evidence to suggest pelvic or peritoneal tumor seeding since no cases of pelvic or abdominal recurrence were discovered after surgery, while allowing the bladder defect to close spontaneously with catheter drainage.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystoscopy. Laparoscopy / methods. Nephrectomy / methods. Ureter / surgery. Ureteral Neoplasms / surgery. Urinary Bladder / surgery. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406870.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement